High-sensitivity assay gives more reassurance to chest pain patients
[PRESS RELEASE 2017-05-30] For some time now, patients in Sweden’s emergency clinics complaining of chest pain have been evaluated using the “high-sensitivity troponin T” assay. In a large-scale registry study published in The Journal of the American College of Cardiology scientists at Karolinska Institutet show how this more sensitive analytical method has improved evaluation for these patients. Since its introduction, fewer patients diagnosed with “unspecified chest pain” suffer a heart attack or die after being sent home.
Chest pain is one of the most common reasons for emergency medical care. Sometimes the pain can be related to a heart attack, but most of the time the cause of the problem cannot be identified and most patients are sent home with an “unspecified chest pain” diagnosis. However, a few of these people will suffer a heart attack, others will have to undergo unplanned revascularisation, and still others will die within 30 days. The difficulty lies in ascertaining who these patients are when they go to an emergency unit with a chest pain complaint.
To rule out myocardial infarction, doctors normally check the patients’ ECG and a blood test or the cardiac biomarkers troponin T or I. In recent years, however, a new and more sensitive assay has been introduced at Swedish hospitals. The method is called high-sensitivity troponin T, which has been shown by previous studies to be more diagnostically accurate, although whether this accuracy applies to clinical procedures has not been known.
To discover if high-sensitivity troponin T is associated with a lower incidence of cardiovascular events, the researchers conducted a large-scale registry study of 65,000 patients with unspecified chest pain who had been discharged from 16 Swedish emergency clinics between 2006 and 2013 in connection with the introduction of the new method.
They found that the risk of suffering a serious cardiovascular event within 30 days of returning home was much lower in patients discharged from an emergency clinic when the new method was in use than in those examined with the old one. The percentage of those subsequently suffering a heart attack, dying or undergoing unplanned revascularisation dropped from 0.9 to 0.6 per cent.
“Our results are of interest to other countries such as the USA, which is about to change its methods,” says Per Svensson, associate professor and senior lecturer at Karolinska Institutet’s Department of Medicine in Solna.
However, amongst the patients who had been discharged from hospital after being admitted for an unspecified chest pain diagnosis, the risk of suffering serious events increased after the change in method. In this group, 7.2 per cent of patients with the new method in use were affected, compared with 3.4 per cent who were examined in the former way. These particular patients also had a higher risk profile after the change in method.
“We may conclude from the results of our study that examination using high-sensitivity troponin is associated with fewer serious cardiac events and an improvement in risk profile for patients released from emergency clinics with unspecified chest pain,” says Dr Svensson. “The opposite was observed in patients sent home after admission to hospital, which suggests that high-risk patients are identified and hospitalised more frequently. We therefore conclude that high-sensitivity troponin has helped to improve the evaluation of emergency patients with unspecified chest pain.”
The study was financed by Karolinska Institutet.
Publication: “Outcomes in Patients With Chest Pain Discharged After Evaluation Using a High-Sensitivity Troponin T Assay”, Atosa Nejatian, Åsa Omstedt, Jonas Höijer, L.O. Hansson, Therese Djärv, Kai M. Eggers, Per Svensson, Journal of the American College of Cardiology (JACC), 30 May 2017, 69(21):2622-2630, doi:10.1016/j.jacc.2017.03.586, doi:10.1016/j.jacc.2017.03.586
For more information, please contact:
Per Svensson, senior lecturer, associate professor
Department of Medicine, Solna, Karolinska Institutet
Phone: +46 (0)70 379 74 97
Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.